Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$45.61M+3.7%-$42.76M+10.8%-$45.86M-3.5%-$47.3M-22.0%-$47.35M-41.1%
$141K-5.4%$144K-2.0%$151K+4.9%$149K+4.2%$149K+7.2%
$6.17M+51.4%$5.19M+44.5%$4.75M+48.2%$4.33M+48.6%$4.07M+75.8%
-$45.3M-9.8%-$42.09M-10.0%-$44.01M-25.5%-$42.68M-30.2%-$41.27M-21.4%
-$67.19M-$94.11M-$87.37M-$28.77M
$112.53M+60.3%$121.01M+96.8%$172.2M+1,628%$175.55M$70.22M
$38K-99.3%-$15.18M-993%$40.82M+512%$104.1M+13,293%$5.56M+158%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Trevi Therapeutics, Inc. generate?
Trevi Therapeutics, Inc. (TRVI) generated -$45.3M in operating cash flow over the trailing twelve months.
What is Trevi Therapeutics, Inc.'s free cash flow?
After $143.0K of capital expenditures, Trevi Therapeutics, Inc.'s free cash flow was -$44.9M over the trailing twelve months, down 35.4% year over year.
Where does Trevi Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Trevi Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.